BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31028221)

  • 1. Comparison of PANAMutyper and PNAClamp for Detecting KRAS Mutations from Patients With Malignant Pleural Effusion.
    Choi SY; Kim HW; Jeon SH; Kim BN; Kang N; Yeo CD; Park CK; Kim YK; Lee YH; Lee KY; Lee SH; Park JY; Park MS; Yim HW; Kim SJ
    In Vivo; 2019; 33(3):945-954. PubMed ID: 31028221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting
    Jeon SH; Kim HW; Kim BN; Kang N; Yeo CD; Park CK; Kim YK; Lee YH; Kim TJ; Lee KY; Lee SH; Park JY; Park MS; Yim HW; Kim SJ
    In Vivo; 2019; 33(2):595-603. PubMed ID: 30804147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of PNA clamping and direct sequencing for detecting KRAS mutations in matched tumour tissue, cell block, pleural effusion and serum from patients with malignant pleural effusion.
    Kang JY; Park CK; Yeo CD; Lee HY; Rhee CK; Kim SJ; Kim SC; Kim YK; Park MS; Yim HW
    Respirology; 2015 Jan; 20(1):138-46. PubMed ID: 25302858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K-ras and rho A mutations in malignant pleural effusion.
    Nakamoto M; Teramoto H; Matsumoto S; Igishi T; Shimizu E
    Int J Oncol; 2001 Nov; 19(5):971-6. PubMed ID: 11604996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
    Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
    Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
    Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
    Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
    DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
    J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
    Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
    Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach.
    Chen CL; Chen CK; Ho CL; Chi WM; Yeh CH; Hu SP; Friebe P; Palmer S; Huang CS
    Mol Diagn Ther; 2019 Oct; 23(5):645-656. PubMed ID: 31347028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
    Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
    Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
    Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
    Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
    Park JK; Lee YJ; Lee JK; Lee KT; Choi YL; Lee KH
    Oncotarget; 2017 Jan; 8(2):3519-3527. PubMed ID: 27974679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
    BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
    Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
    Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of the FHIT and p16 mRNA loss and the K-ras gene mutation in pleural fluids for malignant pleural effusion.
    Li J; Bao QL; Wang Y; Hu YM; Chen P
    Cancer Biomark; 2013; 13(1):49-58. PubMed ID: 23736021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant KRAS promotes malignant pleural effusion formation.
    Agalioti T; Giannou AD; Krontira AC; Kanellakis NI; Kati D; Vreka M; Pepe M; Spella M; Lilis I; Zazara DE; Nikolouli E; Spiropoulou N; Papadakis A; Papadia K; Voulgaridis A; Harokopos V; Stamou P; Meiners S; Eickelberg O; Snyder LA; Antimisiaris SG; Kardamakis D; Psallidas I; Marazioti A; Stathopoulos GT
    Nat Commun; 2017 May; 8():15205. PubMed ID: 28508873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
    Auner V; Kriegshäuser G; Tong D; Horvat R; Reinthaller A; Mustea A; Zeillinger R
    BMC Cancer; 2009 Apr; 9():111. PubMed ID: 19358724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC.
    Qiao M; Li D; He Y; Zhang C; Chi H; Li X; Cui Q; Li S; Jiao Y; Wei Y
    Emerg Med Int; 2022; 2022():3112281. PubMed ID: 35721255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecting epidermal growth factor receptor (EGFR) mutation status of malignant pleural effusion.
    Wang L; Guo T; Lu Q; Yan X; Zhong D; Zhang Z; Ni Y; Han Y; Cui D; Li X; Huang L
    ACS Appl Mater Interfaces; 2015 Jan; 7(1):359-69. PubMed ID: 25495142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.